Product Description
Rivaroxaban is used to treat and manage venous thromboembolism as a postoperative thromboprophylaxis for patients undergoing orthopedic surgery to prevent stroke in patients with non-valvular atrial fibrillation and recently has received approval as an add-on drug for secondary prevention of acute coronary syndrome and peripheral arterial disease. It is a novel oral anticoagulant (NOAC) and is commonly referred to as a blood thinner agent. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/32491434/)
Mechanisms of Action: FXa Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Botswana, Brazil, Cameroon, Canada, China, Egypt, Ethiopia, France, Germany, India, Indonesia, Kazakhstan, Kenya, Kyrgyzstan, Malawi, Malaysia, Mexico, Mozambique, Nepal, Nigeria, Pakistan, Paraguay, Philippines, Rwanda, Saudi Arabia, Singapore, South Africa, Sudan, Switzerland, Taiwan, Tanzania, Tunisia, Uganda, Zambia, Zimbabwe
Active Clinical Trial Count: 14
Highest Development Phases
Phase 3: Kidney Diseases|Kidney Failure, Chronic|Multiple Myeloma|Myelofibrosis|Polycythemia Vera|Rheumatic Heart Disease|Thrombocythemia, Essential|Thrombosis|Venous Thromboembolism
Phase 2: Liver Cirrhosis
Phase 1: Atrial Fibrillation|Embolism and Thrombosis|Healthy Volunteers|Heart Failure, Acute|Hypertension, Pulmonary|Ischemic Attack, Transient|Ischemic Stroke|Malnutrition|Obesity, Morbid|Pulmonary Embolism|Venous Thrombosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TRACK | P3 |
Recruiting |
Kidney Failure, Chronic |
2027-06-30 |
|
| AVAJAK | P3 |
Active, not recruiting |
Thrombocythemia, Essential|Polycythemia Vera|Myelofibrosis |
2026-06-03 |
|
| TRACK_001 | P3 |
Unknown Status |
Kidney Diseases |
2026-03-01 |
|
| BARIVA | P2 |
Completed |
Venous Thromboembolism |
2023-12-31 |